PRDX2 and colorectal carcinoma: Then, colony formation assay showed that conoidin A treatment sufficiently inhibited the proliferation of HT29and SW480 cells, not RKO cells, which implicates a therapeutic potential of PrxII inhibition to selectively target human APC-mutant CRC cells (Fig. 6d).